Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2023 · 10-Q
Revenue$10.89M$10.89M+5.7% vs Q2 2022 Net Income$872.20K$872.20KN/M vs Q2 2022 EPS Diluted$0.06$0.06N/M vs Q2 2022 Operating Income$22,859N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$5,163,168+135.4% Margins · derivedOperating margin0.2%+18.1 pt vs Q2 2022
Net margin8.0%+21.0 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end